Search results
Results From The WOW.Com Content Network
Celldex Therapeutics, Inc. (NASDAQ: CLDX) stock tanked Monday after the company effected a 15-to-1 reverse stock split that was first announced two days ago. The reverse split pushed Celldex’s ...
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
Varlilumab (INN; [1] development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. [2] It is an anti-CD27 antibody and helps activate T-cells.
Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, [7] who acquired CuraGen in 2009. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics.
Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.